Core-Shell Fiber Membrane for Sustained Simvastatin Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone defect treatments, such as autogenous and allogeneic bone grafts, face limitations in biocompatibility, drug release control, and efficacy in promoting bone regeneration, with traditional fiber materials prone to initial burst release and inflammatory responses.
Innovation Solution
A fiber membrane with a core-shell structure is developed, where the core contains simvastatin and a first spinnable polymer, and the shell contains hydroxyapatite and a second spinnable polymer, using coaxial electrospinning to achieve sustained drug release and enhanced bone regeneration through controlled release of simvastatin and synergistic effects with hydroxyapatite.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional electrospinning is used to prepare fiber materials, then the fabrication process is simple, but the drugs cannot control release and are prone to initial burst release
Solution Approach 1:
The fiber is divided into a core region containing the drug (simvastatin) and a shell region containing hydroxyapatite and spinnable polymer. This segmentation allows the core to provide sustained drug release while the shell provides structural support and controlled degradation, preventing initial burst release and enabling reliable drug release control throughout the treatment period.
Solution Approach 2:
The fiber membrane combines multiple materials with complementary properties: simvastatin (osteogenic drug), hydroxyapatite (bone mineral), and biodegradable spinnable polymer. This composite structure enables simultaneous achievement of bone regeneration promotion, controlled drug release, and mechanical stability, resolving the contradiction between fabrication simplicity and reliable drug release control.
2Reliability
If autogenous bone graft is used, then the repair effect is best, but excessive use brings new trauma and complications
Solution Approach 1:
The fiber membrane acts as an intermediary carrier that delivers osteogenic drugs and bone minerals to the defect site without requiring removal of healthy bone tissue. The simvastatin-loaded core provides osteogenic stimulation while the hydroxyapatite shell provides structural support, achieving bone regeneration without the trauma and complications associated with autogenous grafting.
Solution Approach 2:
The invention changes the delivery parameters by using a controlled-release fiber membrane system. The core-shell structure enables sustained release of simvastatin over time, providing continuous osteogenic stimulation without the need for excessive bone harvesting. This parameter change in drug delivery timing and concentration eliminates the harmful effects of excessive autogenous graft use.
3Object-affected harmful factors
If allogeneic bone graft is used, then partial problems are overcome, but it is limited by donor source and rejection
Solution Approach 1:
The fiber membrane system serves the bone regeneration needs without requiring external donor sources. The simvastatin and hydroxyapatite are incorporated directly into the fiber structure during manufacturing, creating a self-contained osteogenic system that eliminates dependence on donor availability and reduces rejection risks associated with allogeneic grafts.
Solution Approach 2:
The invention changes the source parameter from biological donors to manufactured fiber membranes with controlled composition. By precisely controlling the core-shell structure and material composition during fabrication, the system provides consistent osteogenic properties without the variability and limitations of donor sources, overcoming both the benefits and drawbacks of allogeneic grafting.
4Adaptability or versatility
If artificial bone materials are used, then customization according to bone properties is possible, but biocompatibility and acceleration effect are required
Solution Approach 1:
The fiber membrane applies local quality by concentrating osteogenic drugs (simvastatin) in the core region and bone minerals (hydroxyapatite) in the shell region. This localized distribution provides customized osteogenic stimulation exactly where needed at the bone defect site, while maintaining biocompatibility through the use of natural bone-like materials and controlled release mechanisms.
Solution Approach 2:
The composite fiber membrane combines simvastatin, hydroxyapatite, and biodegradable polymer in a core-shell structure that simultaneously provides customization capability and reliable biocompatibility. The hydroxyapatite shell ensures biocompatibility and structural integrity, while the simvastatin core provides accelerated bone regeneration, meeting both requirements of artificial bone materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fiber membrane provides a sustained release of simvastatin for up to 28 days, promoting continuous bone regeneration and improving biocompatibility, thereby addressing the limitations of existing treatments.
Implementation Method 1
Electrospinning is a common technique for bottom-up fabrication of nanofibers using high-voltage electrostatics to draw working fluids into filaments.
Implementation Method 2
the simvastatin in the fiber leaves the fiber with the diffusion of water
Data Source
AI summary
The present disclosure provides a fiber membrane and a preparation method and use thereof, and belongs to the field of biological materials. The fiber membrane includes a fiber with a core-shell structure, where a core of the fiber includes simvastatin and a first spinnable polymer, and a shell of the fiber includes hydroxyapatite and a second spinnable polymer. In the fiber, a release of the simvastatin mainly depends on a rate of water invasion. After water invades the fiber, the simvastatin in the fiber leaves the fiber with the diffusion of water. In the present disclosure, a barrier function of the shell prevents moisture from entering the core. Therefore, the simvastatin in the core cannot leave the fiber with the diffusion of water molecules in an early stage, and a release rate of drugs is slowed down in the early stage, thereby controlling sustained release of the drugs.